Ocrelizumab, rituximab, ofatumumab, ublituximab, inebilizumab, and evobrutinib are immunotherapies that target various B cell-related proteins. Most of these treatments have proven efficacy in relapsing and progressive forms of MS and neuromyelitis optica spectrum disease (NMOSD) or are in advanced stages of clinical development. Currently, ocrelizumab and inebilizumab are licensed for treatment of MS and NMOSD, respectively. This part of the review focuses on monoclonal antibody B cell-depleting strategies in NMOSD and the emerging related myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G-associated disease (MOGAD). Case series and phase 2/3 studies in these inflammatory disorders are assessed. The safety profile of long-term B-cell depletion in MS, NMOSD, and MOGAD will be highlighted. Finally implications of the current coronavirus disease 2019 pandemic on the management of patients with these disorders and the use of B cell-depleting agents will be discussed.

From the Department of Neurology UCSF Weill Institute of Neurosciences University of California at San Francisco

See more in PubMed

Fujihara K, Cook LJ. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics. Curr Opin Neurol 2020;33:300–308. PubMed

Bennett JL, O'Connor KC, Bar-Or A, et al. . B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e104. doi: 10.1212/NXI.0000000000000104. PubMed DOI PMC

Cotzomi E, Stathopoulos P, Lee CS, et al. . Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 2019;142:1598–1615. PubMed PMC

Mader S, Kümpfel T, Meinl E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Curr Opin Neurol 2020;33:362–371. PubMed

Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016;73:1342–1348. PubMed

Gao F, Chai B, Gu C, et al. . Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019;19:36. PubMed PMC

Annovazzi P, Capobianco M, Moiola L, et al. . Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study. J Neurol 2016;263:1727–1735. PubMed

Trebst C, Jarius S, Berthele A, et al. . Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16. PubMed PMC

Cabre P, Mejdoubi M, Jeannin S, et al. . Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol 2018;265:917–925. PubMed

Radaelli M, Moiola L, Sangalli F, et al. . Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 2016;22:511–519. PubMed

Chamberlain N, Massad C, Oe T, Cantaert T, Herold KC, Meffre E. Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest 2016;126:282–287. PubMed PMC

Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70:1110–1117. PubMed

Kim SH, Hyun JW, Kim HJ. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochem Int 2019;130:104347. PubMed

Cohen M, Romero G, Bas J, et al. . Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study. J Neurol Sci 2017;373:335–338. PubMed

Evangelopoulos ME, Andreadou E, Koutsis G, et al. . Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. J Neurol Sci 2017;372:92–96. PubMed

Novi G, Bovis F, Capobianco M, et al. . Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2019;36:101430. PubMed

Paolilo RB, Hacohen Y, Yazbeck E, et al. . Treatment and outcome of aquaporin-4 antibody-positive NMOSD: a multinational pediatric study. Neurol Neuroimmunol Neuroinflamm 2020;7:e387. doi: 10.1212/NXI.0000000000000104. PubMed DOI PMC

Tahara M, Oeda T, Okada K, et al. . Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020;19:298–306. PubMed

Hartung HP, Aktas O. Old and new breakthroughs in neuromyelitis optica. Lancet Neurol 2020;19:280–281. PubMed

Trewin BP, Adelstein S, Spies JM, et al. . Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Mult Scler Relat Disord 2020;43:102175. PubMed

Herbst R, Wang Y, Gallagher S, et al. . B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010;335:213–222. PubMed

Ward E, Mittereder N, Kuta E, et al. . A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011;155:426–437. PubMed

Chen D, Gallagher S, Monson NL, Herbst R, Wang Y. Inebilizumab, a B Cell-Depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med 2016;5:107. PubMed PMC

Agius MA, Klodowska-Duda G, Maciejowski M, et al. . Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler 2019;25:235–245. PubMed PMC

Cree BAC, Bennett JL, Kim HJ, et al. . Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352–1363. PubMed

Gallagher S, Turman S, Yusuf I, et al. . Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice. Int Immunopharmacol 2016;36:205–212. PubMed

Stüve O, Warnke C, Deason K, et al. . CD19 as a molecular target in CNS autoimmunity. Acta Neuropathol 2014;128:177–190. PubMed PMC

Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore) 2019;98:e15944. PubMed PMC

Traboulsee A, Greenberg BM, Bennett JL, et al. . Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020;19:402–412. PubMed PMC

Zhang C, Zhang M, Qiu W, et al. . Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020;19:391–401. PubMed PMC

Bennett JL, Greenberg B, Traboulsee A, et al. . Efficacy of satralizumab as monotherapy in pre-specified subgroups of sakurastar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD). Mult Scler Relat Disord 2020;37:101576.

Jarius S, Ruprecht K, Kleiter I, et al. . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280. PubMed PMC

Papathanasiou A, Tanasescu R, Davis J, et al. . MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. J Neurol 2020;267:359–368. PubMed

Höftberger R, Guo Y, Flanagan EP, et al. . The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol 2020;139:875–892. PubMed PMC

Jurynczyk M, Messina S, Woodhall MR, et al. . Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128–3138. PubMed

Takai Y, Misu T, Kaneko K, et al. . Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 2020;143:1431–1446. PubMed

Ciotti JR, Eby NS, Wu GF, Naismith RT, Chahin S, Cross AH. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. Mult Scler Relat Disord 2020;45:102399. PubMed

Spadaro M, Winklmeier S, Beltrán E, et al. . Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol 2018;84:315–328. PubMed

Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89–102. PubMed

Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol 2017;8:529. PubMed PMC

Winklmeier S, Schlüter M, Spadaro M, et al. . Identification of circulating MOG-specific B cells in patients with MOG antibodies. Neurol Neuroimmunol Neuroinflamm 2019;6:625. doi: 10.1212/NXI.0000000000000104. PubMed DOI PMC

Li X, Wang L, Zhou L, et al. . The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. Mult Scler Relat Disord 2019;36:101397. PubMed

Hacohen Y, Wong YY, Lechner C, et al. . Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018;75:478–487. PubMed PMC

Durozard P, Rico A, Boutiere C, et al. . Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 2020;87:256–266. PubMed

Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. . Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord 2020;44:102251. PubMed PMC

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016;12:217–233. PubMed

Salzer J, Svenningsson R, Alping P, et al. . Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 2016;87:2074–2081. PubMed PMC

Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020;7:1477–1487. PubMed PMC

Luna G, Alping P, Burman J, et al. . Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020;77:184–191. PubMed PMC

Airas L, Nylund M, Mannonen I, Matilainen M, Sucksdorff M, Rissanen E. Rituximab in the treatment of multiple sclerosis in the hospital district of southwest Finland. Mult Scler Relat Disord 2020;40:101980. PubMed

Caldito NG, Shirani A, Salter A, Stuve O. Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database. Mult Scler 2020. doi: 10.1177/1352458520949986. PubMed

Alping P, Askling J, Burman J, et al. . Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 2020;87:688–699. PubMed

van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 2015;42:1761–1766. PubMed

Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf 2020;19:1069–1094. PubMed

Hauser SL, Kappos L, Arnold DL, et al. . Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 2020;95:e1854–e1867. PubMed PMC

Hauser SL, Kappos L, Montalban X, et al. . Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Presented at the 70th American Academy of Neurology (AAN) Annual Meeting; April 21–27, 2018; Los Angeles, CA, USA; Platform presentation number S36.001 [online]. Available at: ocreposters.com/uploads/AAN%202018%20General%20Safety_Platform_Global_Hauser%20et%20al_Updated.pdf. Accessed June 15, 2020.

Montalban X, Hauser SL, Kappos L, et al. . Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–220. PubMed

Hauser SL, Kappos L, Montalban X, et al. . Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Presented at the 6th Congress of the European Academy of Neurology (EAN) [online]. Available at: medically.roche.com/en/search/pdfviewer.ed54f34c-1b9b-461a-82ed-dac932793643.html?cid=slpsxx2005nexxean2020. Accessed June 15, 2020.

Ciardi MR, Iannetta M, Zingaropoli MA, et al. . Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis 2019;6:ofy356. PubMed PMC

Nicolini LA, Canepa P, Caligiuri P, et al. . Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis. JAMA Neurol 2019;76:866–867. PubMed PMC

Additional e-references (e1-e37) available at: links.lww.com/NXI/A347.

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial